EMMA (Enhancing Medical Management with Omics Approaches in Women’s Health) is a new clinical study aiming to improve how we diagnose and monitor endometriosis, a condition that affects around 1 in 10 women but is often missed or misdiagnosed for years.

​

We also know that women with endometriosis may have a higher risk of developing certain gynaecological cancers, such as ovarian cancer. However, there are currently no reliable tests to identify who is most at risk, or to help doctors detect these changes early.

​

What EMMA aims to do

​

• Develop better ways to diagnose endometriosis using simple tests like blood or urine

• Identify biomarkers (measurable changes in the body) that could show if someone is at higher risk of cancer

• Understand how endometriosis changes over time, and which forms are more serious

• Help doctors offer more personalised care based on risk and disease type

​

How the study works

​

The EMMA team will collect blood, urine and tissue samples from women with and without endometriosis, and use advanced lab techniques to look for patterns in proteins, genes and metabolites.

​

By doing this, we hope to pave the way for earlier diagnosis, better monitoring and safer long term care for women living with endometriosis.

​

EMMA publications

​

Watch this space: EMMA is in its early stages, and publications and study updates will be shared here as results become available.

​

In the meantime, you can explore related omics research from Clinical Hub Aberystwyth on our Publications page.